SGR-1505 is a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor.

MALT1 is a key mediator of the NF-κB signaling pathway and the main driver of a subset of B-cell lymphomas. Ongoing, external clinical studies are showing promise of MALT1 as a potential therapeutic target for the treatment of several non-Hodgkin's B-cell lymphomas.

SGR-3515 is a dual Wee1/Myt1 inhibitor being developed for the treatment of solid tumors.

Wee1 and Myt1 are key regulators of the cell cycle, and their inhibition can lead to selective killing of cancer cells with DNA damage repair defects. Preclinical studies have demonstrated promising activity in various solid tumor models.

SGR-4174 is a SOS1 inhibitor targeting RAS-driven cancers.

SOS1 is a key activator of RAS proteins, which are frequently mutated in human cancers. Inhibition of SOS1 represents a promising approach to target RAS-driven tumors that are often resistant to conventional therapies.

EGFR^C797S is a third-generation EGFR inhibitor designed to overcome C797S-mediated resistance.

This program targets non-small cell lung cancers harboring EGFR mutations, including those with acquired resistance to earlier generation EGFR inhibitors due to the C797S mutation.

SGR-3515 is a dual Wee1/Myt1 inhibitor being developed for the treatment of solid tumors.

Wee1 and Myt1 are key regulators of the cell cycle, and their inhibition can lead to selective killing of cancer cells with DNA damage repair defects. Preclinical studies have demonstrated promising activity in various solid tumor models.

SGR-3515 is a dual Wee1/Myt1 inhibitor being developed for the treatment of solid tumors.

Wee1 and Myt1 are key regulators of the cell cycle, and their inhibition can lead to selective killing of cancer cells with DNA damage repair defects. Preclinical studies have demonstrated promising activity in various solid tumor models.

SGR-3515 is a dual Wee1/Myt1 inhibitor being developed for the treatment of solid tumors.

Wee1 and Myt1 are key regulators of the cell cycle, and their inhibition can lead to selective killing of cancer cells with DNA damage repair defects. Preclinical studies have demonstrated promising activity in various solid tumor models.

SGR-3515 is a dual Wee1/Myt1 inhibitor being developed for the treatment of solid tumors.

Wee1 and Myt1 are key regulators of the cell cycle, and their inhibition can lead to selective killing of cancer cells with DNA damage repair defects. Preclinical studies have demonstrated promising activity in various solid tumor models.

NLRP3 is an inhibitor of the NLRP3 inflammasome, a key regulator of the inflammatory response.

This program is being developed for various inflammatory diseases driven by excessive NLRP3 activation, including autoinflammatory conditions and neurodegenerative disorders.